APO Research
Talk to an analyst

APO RESEARCH · REPORT

Chagas Disease Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Chagas Disease Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025197 pages

Choose your research edition.

Industry ResearchChagas Disease Drug Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Chagas Disease Drug Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Chagas Disease Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Chagas Disease Drug Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Chagas Disease Drug Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Chagas Disease Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Chagas Disease Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Chagas Disease Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Chagas Disease Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Chagas Disease Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Chagas Disease Drug include Eisai Co Ltd, Sanofi, Novartis AG, GlaxoSmithKline Plc, Bayer AG, AstraZeneca Plc, Oblita Therapeutics BVBA, Merck & Co Inc and Kancera AB, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Chagas Disease Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Chagas Disease Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Chagas Disease Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Chagas Disease Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Chagas Disease Drug Segment by Company

Eisai Co Ltd

Sanofi

Novartis AG

GlaxoSmithKline Plc

Bayer AG

AstraZeneca Plc

Oblita Therapeutics BVBA

Merck & Co Inc

Kancera AB

Humanigen Inc

Grupo Praxis Pharmaceutical SA

Daiichi Sankyo Co Ltd

Chagas Disease Drug Segment by Type

Cz-007

Cz-008

D-121

DNDI-0690

EPLBS-1246

EPLBS-967

Others

Chagas Disease Drug Segment by Application

Hospital

Clinic

Others

Chagas Disease Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chagas Disease Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Chagas Disease Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chagas Disease Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Chagas Disease Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Chagas Disease Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Chagas Disease Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Chagas Disease Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Chagas Disease Drug Industry Trends Table 2. Chagas Disease Drug Industry Drivers Table 3. Chagas Disease Drug Industry Opportunities and Challenges Table 4. Chagas Disease Drug Industry Restraints Table 5. Global Chagas Disease Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Chagas Disease Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Chagas Disease Drug Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Chagas Disease Drug Sales Market Share by Manufacturers Table 9. Global Chagas Disease Drug Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Chagas Disease Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Chagas Disease Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Chagas Disease Drug Manufacturers, Product Type & Application Table 13. Global Chagas Disease Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Chagas Disease Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Cz-007 Table 17. Major Manufacturers of Cz-008 Table 18. Major Manufacturers of D-121 Table 19. Major Manufacturers of DNDI-0690 Table 20. Major Manufacturers of EPLBS-1246 Table 21. Major Manufacturers of EPLBS-967 Table 22. Major Manufacturers of Others Table 23. Global Chagas Disease Drug Sales by Type 2021 VS 2025 VS 2032 (k units) Table 24. Global Chagas Disease Drug Sales by Type (2021-2026) & (k units) Table 25. Global Chagas Disease Drug Sales by Type (2027-2032) & (k units) Table 26. Global Chagas Disease Drug Sales Market Share by Type (2021-2026) Table 27. Global Chagas Disease Drug Sales Market Share by Type (2027-2032) Table 28. Global Chagas Disease Drug Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 29. Global Chagas Disease Drug Revenue by Type (2021-2026) & (k units) Table 30. Global Chagas Disease Drug Revenue by Type (2027-2032) & (k units) Table 31. Global Chagas Disease Drug Revenue Market Share by Type (2021-2026) Table 32. Global Chagas Disease Drug Revenue Market Share by Type (2027-2032) Table 33. Major Manufacturers of Hospital Table 34. Major Manufacturers of Clinic Table 35. Major Manufacturers of Others Table 36. Global Chagas Disease Drug Sales by Application 2021 VS 2025 VS 2032 (k units) Table 37. Global Chagas Disease Drug Sales by Application (2021-2026) & (k units) Table 38. Global Chagas Disease Drug Sales by Application (2027-2032) & (k units) Table 39. Global Chagas Disease Drug Sales Market Share by Application (2021-2026) Table 40. Global Chagas Disease Drug Sales Market Share by Application (2027-2032) Table 41. Global Chagas Disease Drug Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 42. Global Chagas Disease Drug Revenue by Application (2021-2026) & (k units) Table 43. Global Chagas Disease Drug Revenue by Application (2027-2032) & (k units) Table 44. Global Chagas Disease Drug Revenue Market Share by Application (2021-2026) Table 45. Global Chagas Disease Drug Revenue Market Share by Application (2027-2032) Table 46. Global Chagas Disease Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 47. Global Chagas Disease Drug Sales by Region (2021-2026) & (k units) Table 48. Global Chagas Disease Drug Sales Market Share by Region (2021-2026) Table 49. Global Chagas Disease Drug Sales Forecasted by Region (2027-2032) & (k units) Table 50. Global Chagas Disease Drug Sales Forecasted Market Share by Region (2027-2032) Table 51. North America Chagas Disease Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 52. North America Chagas Disease Drug Sales by Country (2021-2026) & (k units) Table 53. North America Chagas Disease Drug Sales by Country (2027-2032) & (k units) Table 54. Europe Chagas Disease Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Europe Chagas Disease Drug Sales by Country (2021-2026) & (k units) Table 56. Europe Chagas Disease Drug Sales by Country (2027-2032) & (k units) Table 57. Asia Pacific Chagas Disease Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 58. Asia Pacific Chagas Disease Drug Sales by Country (2021-2026) & (k units) Table 59. Asia Pacific Chagas Disease Drug Sales by Country (2027-2032) & (k units) Table 60. South America, Middle East and Africa Chagas Disease Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 61. South America, Middle East and Africa Chagas Disease Drug Sales by Country (2021-2026) & (k units) Table 62. South America, Middle East and Africa Chagas Disease Drug Sales by Country (2027-2032) & (k units) Table 63. Global Chagas Disease Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 64. Global Chagas Disease Drug Revenue by Region (2021-2026) & (US$ Million) Table 65. Global Chagas Disease Drug Revenue by Region (2027-2032) & (US$ Million) Table 66. Global Chagas Disease Drug Revenue Market Share by Region (2021-2026) Table 67. Global Chagas Disease Drug Revenue Market Share by Region (2027-2032) Table 68. Eisai Co Ltd Company Information Table 69. Eisai Co Ltd Business Overview Table 70. Eisai Co Ltd Chagas Disease Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Eisai Co Ltd Chagas Disease Drug Product Portfolio Table 72. Eisai Co Ltd Recent Development Table 73. Sanofi Company Information Table 74. Sanofi Business Overview Table 75. Sanofi Chagas Disease Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Sanofi Chagas Disease Drug Product Portfolio Table 77. Sanofi Recent Development Table 78. Novartis AG Company Information Table 79. Novartis AG Business Overview Table 80. Novartis AG Chagas Disease Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Novartis AG Chagas Disease Drug Product Portfolio Table 82. Novartis AG Recent Development Table 83. GlaxoSmithKline Plc Company Information Table 84. GlaxoSmithKline Plc Business Overview Table 85. GlaxoSmithKline Plc Chagas Disease Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. GlaxoSmithKline Plc Chagas Disease Drug Product Portfolio Table 87. GlaxoSmithKline Plc Recent Development Table 88. Bayer AG Company Information Table 89. Bayer AG Business Overview Table 90. Bayer AG Chagas Disease Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Bayer AG Chagas Disease Drug Product Portfolio Table 92. Bayer AG Recent Development Table 93. AstraZeneca Plc Company Information Table 94. AstraZeneca Plc Business Overview Table 95. AstraZeneca Plc Chagas Disease Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. AstraZeneca Plc Chagas Disease Drug Product Portfolio Table 97. AstraZeneca Plc Recent Development Table 98. Oblita Therapeutics BVBA Company Information Table 99. Oblita Therapeutics BVBA Business Overview Table 100. Oblita Therapeutics BVBA Chagas Disease Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Oblita Therapeutics BVBA Chagas Disease Drug Product Portfolio Table 102. Oblita Therapeutics BVBA Recent Development Table 103. Merck & Co Inc Company Information Table 104. Merck & Co Inc Business Overview Table 105. Merck & Co Inc Chagas Disease Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Merck & Co Inc Chagas Disease Drug Product Portfolio Table 107. Merck & Co Inc Recent Development Table 108. Kancera AB Company Information Table 109. Kancera AB Business Overview Table 110. Kancera AB Chagas Disease Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Kancera AB Chagas Disease Drug Product Portfolio Table 112. Kancera AB Recent Development Table 113. Humanigen Inc Company Information Table 114. Humanigen Inc Business Overview Table 115. Humanigen Inc Chagas Disease Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Humanigen Inc Chagas Disease Drug Product Portfolio Table 117. Humanigen Inc Recent Development Table 118. Grupo Praxis Pharmaceutical SA Company Information Table 119. Grupo Praxis Pharmaceutical SA Business Overview Table 120. Grupo Praxis Pharmaceutical SA Chagas Disease Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. Grupo Praxis Pharmaceutical SA Chagas Disease Drug Product Portfolio Table 122. Grupo Praxis Pharmaceutical SA Recent Development Table 123. Daiichi Sankyo Co Ltd Company Information Table 124. Daiichi Sankyo Co Ltd Business Overview Table 125. Daiichi Sankyo Co Ltd Chagas Disease Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. Daiichi Sankyo Co Ltd Chagas Disease Drug Product Portfolio Table 127. Daiichi Sankyo Co Ltd Recent Development Table 128. Key Raw Materials Table 129. Raw Materials Key Suppliers Table 130. Chagas Disease Drug Distributors List Table 131. Chagas Disease Drug Customers List Table 132. Research Programs/Design for This Report Table 133. Authors List of This Report Table 134. Secondary Sources Table 135. Primary Sources List of Figures Figure 1. Chagas Disease Drug Product Image Figure 2. Global Chagas Disease Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Chagas Disease Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Chagas Disease Drug Sales (2021-2032) & (k units) Figure 5. Global Chagas Disease Drug Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Chagas Disease Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Cz-007 Image Figure 9. Cz-008 Image Figure 10. D-121 Image Figure 11. DNDI-0690 Image Figure 12. EPLBS-1246 Image Figure 13. EPLBS-967 Image Figure 14. Others Image Figure 15. Global Chagas Disease Drug Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 16. Global Chagas Disease Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 17. Global Chagas Disease Drug Sales Market Share by Type (2021-2032) Figure 18. Global Chagas Disease Drug Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 19. Global Chagas Disease Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Chagas Disease Drug Revenue Market Share by Type (2021-2032) Figure 21. Hospital Image Figure 22. Clinic Image Figure 23. Others Image Figure 24. Global Chagas Disease Drug Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 25. Global Chagas Disease Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 26. Global Chagas Disease Drug Sales Market Share by Application (2021-2032) Figure 27. Global Chagas Disease Drug Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 28. Global Chagas Disease Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 29. Global Chagas Disease Drug Revenue Market Share by Application (2021-2032) Figure 30. North America Chagas Disease Drug Sales and Growth Rate (2021-2032) & (k units) Figure 31. North America Chagas Disease Drug Sales Market Share by Country (2021-2032) Figure 32. U.S. Chagas Disease Drug Sales and Growth Rate (2021-2032) & (k units) Figure 33. Canada Chagas Disease Drug Sales and Growth Rate (2021-2032) & (k units) Figure 34. Mexico Chagas Disease Drug Sales and Growth Rate (2021-2032) & (k units) Figure 35. Europe Chagas Disease Drug Sales and Growth Rate (2021-2032) & (k units) Figure 36. Europe Chagas Disease Drug Sales Market Share by Country (2021-2032) Figure 37. Germany Chagas Disease Drug Sales and Growth Rate (2021-2032) & (k units) Figure 38. France Chagas Disease Drug Sales and Growth Rate (2021-2032) & (k units) Figure 39. U.K. Chagas Disease Drug Sales and Growth Rate (2021-2032) & (k units) Figure 40. Italy Chagas Disease Drug Sales and Growth Rate (2021-2032) & (k units) Figure 41. Netherlands Chagas Disease Drug Sales and Growth Rate (2021-2032) & (k units) Figure 42. Asia Pacific Chagas Disease Drug Sales and Growth Rate (2021-2032) & (k units) Figure 43. Asia Pacific Chagas Disease Drug Sales Market Share by Country (2021-2032) Figure 44. China Chagas Disease Drug Sales and Growth Rate (2021-2032) & (k units) Figure 45. Japan Chagas Disease Drug Sales and Growth Rate (2021-2032) & (k units) Figure 46. South Korea Chagas Disease Drug Sales and Growth Rate (2021-2032) & (k units) Figure 47. Southeast Asia Chagas Disease Drug Sales and Growth Rate (2021-2032) & (k units) Figure 48. India Chagas Disease Drug Sales and Growth Rate (2021-2032) & (k units) Figure 49. Australia Chagas Disease Drug Sales and Growth Rate (2021-2032) & (k units) Figure 50. South America, Middle East and Africa Chagas Disease Drug Sales and Growth Rate (2021-2032) & (k units) Figure 51. South America, Middle East and Africa Chagas Disease Drug Sales Market Share by Country (2021-2032) Figure 52. Brazil Chagas Disease Drug Sales and Growth Rate (2021-2032) & (k units) Figure 53. South Africa Chagas Disease Drug Sales and Growth Rate (2021-2032) & (k units) Figure 54. Saudi Arabia Chagas Disease Drug Sales and Growth Rate (2021-2032) & (k units) Figure 55. Turkey Chagas Disease Drug Sales and Growth Rate (2021-2032) & (k units) Figure 56. Argentina Chagas Disease Drug Sales and Growth Rate (2021-2032) & (k units) Figure 57. UAE Chagas Disease Drug Sales and Growth Rate (2021-2032) & (k units) Figure 58. Egypt Chagas Disease Drug Sales and Growth Rate (2021-2032) & (k units) Figure 59. Chile Chagas Disease Drug Sales and Growth Rate (2021-2032) & (k units) Figure 60. Global Chagas Disease Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 61. Global Chagas Disease Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 62. North America Chagas Disease Drug Revenue (2021-2032) & (US$ Million) Figure 63. North America Chagas Disease Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Europe Chagas Disease Drug Revenue (2021-2032) & (US$ Million) Figure 65. Europe Chagas Disease Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Asia-Pacific Chagas Disease Drug Revenue (2021-2032) & (US$ Million) Figure 67. Asia-Pacific Chagas Disease Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. South America, Middle East and Africa Chagas Disease Drug Revenue (2021-2032) & (US$ Million) Figure 69. South America, Middle East and Africa Chagas Disease Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 70. Chagas Disease Drug Value Chain Figure 71. Manufacturing Cost Structure Figure 72. Chagas Disease Drug Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Cz-007
  • Cz-008
  • D-121
  • DNDI-0690
  • EPLBS-1246
  • EPLBS-967
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Eisai Co Ltd
  • Sanofi
  • Novartis AG
  • GlaxoSmithKline Plc
  • Bayer AG
  • AstraZeneca Plc
  • Oblita Therapeutics BVBA
  • Merck & Co Inc
  • Kancera AB
  • Humanigen Inc
  • Grupo Praxis Pharmaceutical SA
  • Daiichi Sankyo Co Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Chagas Disease Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Chagas Disease Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Chagas Disease Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Chagas Disease Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Chagas Disease Drug Market Dynamics
  1. 2.1 Chagas Disease Drug Industry Trends
  2. 2.2 Chagas Disease Drug Industry Drivers
  3. 2.3 Chagas Disease Drug Industry Opportunities and Challenges
  4. 2.4 Chagas Disease Drug Industry Restraints
3 Chagas Disease Drug Market by Manufacturers
  1. 3.1 Global Chagas Disease Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Chagas Disease Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Chagas Disease Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Chagas Disease Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Chagas Disease Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Chagas Disease Drug Manufacturers, Product Type & Application
  7. 3.7 Global Chagas Disease Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Chagas Disease Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Chagas Disease Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Chagas Disease Drug Tier 1, Tier 2, and Tier 3
4 Chagas Disease Drug Market by Type
  1. 4.1 Chagas Disease Drug Type Introduction
  2. 4.1.1 Cz-007
  3. 4.1.2 Cz-008
  4. 4.1.3 D-121
  5. 4.1.4 DNDI-0690
  6. 4.1.5 EPLBS-1246
  7. 4.1.6 EPLBS-967
  8. 4.1.7 Others
  9. 4.2 Global Chagas Disease Drug Sales by Type
  10. 4.2.1 Global Chagas Disease Drug Sales by Type (2021 VS 2025 VS 2032)
  11. 4.2.2 Global Chagas Disease Drug Sales by Type (2021-2032)
  12. 4.2.3 Global Chagas Disease Drug Sales Market Share by Type (2021-2032)
  13. 4.3 Global Chagas Disease Drug Revenue by Type
  14. 4.3.1 Global Chagas Disease Drug Revenue by Type (2021 VS 2025 VS 2032)
  15. 4.3.2 Global Chagas Disease Drug Revenue by Type (2021-2032)
  16. 4.3.3 Global Chagas Disease Drug Revenue Market Share by Type (2021-2032)
5 Chagas Disease Drug Market by Application
  1. 5.1 Chagas Disease Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Chagas Disease Drug Sales by Application
  6. 5.2.1 Global Chagas Disease Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Chagas Disease Drug Sales by Application (2021-2032)
  8. 5.2.3 Global Chagas Disease Drug Sales Market Share by Application (2021-2032)
  9. 5.3 Global Chagas Disease Drug Revenue by Application
  10. 5.3.1 Global Chagas Disease Drug Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Chagas Disease Drug Revenue by Application (2021-2032)
  12. 5.3.3 Global Chagas Disease Drug Revenue Market Share by Application (2021-2032)
6 Global Chagas Disease Drug Sales by Region
  1. 6.1 Global Chagas Disease Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Chagas Disease Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Chagas Disease Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Chagas Disease Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Chagas Disease Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Chagas Disease Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Chagas Disease Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Chagas Disease Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Chagas Disease Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Chagas Disease Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Chagas Disease Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Chagas Disease Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Chagas Disease Drug Revenue by Region
  1. 7.1 Global Chagas Disease Drug Revenue by Region
  2. 7.1.1 Global Chagas Disease Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Chagas Disease Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Chagas Disease Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Chagas Disease Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Chagas Disease Drug Revenue (2021-2032)
  8. 7.2.2 North America Chagas Disease Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Chagas Disease Drug Revenue (2021-2032)
  11. 7.3.2 Europe Chagas Disease Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Chagas Disease Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Chagas Disease Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Chagas Disease Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Chagas Disease Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Eisai Co Ltd
  2. 8.1.1 Eisai Co Ltd Company Information
  3. 8.1.2 Eisai Co Ltd Business Overview
  4. 8.1.3 Eisai Co Ltd Chagas Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Eisai Co Ltd Chagas Disease Drug Product Portfolio
  6. 8.1.5 Eisai Co Ltd Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Chagas Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Chagas Disease Drug Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Novartis AG
  14. 8.3.1 Novartis AG Company Information
  15. 8.3.2 Novartis AG Business Overview
  16. 8.3.3 Novartis AG Chagas Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Novartis AG Chagas Disease Drug Product Portfolio
  18. 8.3.5 Novartis AG Recent Developments
  19. 8.4 GlaxoSmithKline Plc
  20. 8.4.1 GlaxoSmithKline Plc Company Information
  21. 8.4.2 GlaxoSmithKline Plc Business Overview
  22. 8.4.3 GlaxoSmithKline Plc Chagas Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 GlaxoSmithKline Plc Chagas Disease Drug Product Portfolio
  24. 8.4.5 GlaxoSmithKline Plc Recent Developments
  25. 8.5 Bayer AG
  26. 8.5.1 Bayer AG Company Information
  27. 8.5.2 Bayer AG Business Overview
  28. 8.5.3 Bayer AG Chagas Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Bayer AG Chagas Disease Drug Product Portfolio
  30. 8.5.5 Bayer AG Recent Developments
  31. 8.6 AstraZeneca Plc
  32. 8.6.1 AstraZeneca Plc Company Information
  33. 8.6.2 AstraZeneca Plc Business Overview
  34. 8.6.3 AstraZeneca Plc Chagas Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 AstraZeneca Plc Chagas Disease Drug Product Portfolio
  36. 8.6.5 AstraZeneca Plc Recent Developments
  37. 8.7 Oblita Therapeutics BVBA
  38. 8.7.1 Oblita Therapeutics BVBA Company Information
  39. 8.7.2 Oblita Therapeutics BVBA Business Overview
  40. 8.7.3 Oblita Therapeutics BVBA Chagas Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Oblita Therapeutics BVBA Chagas Disease Drug Product Portfolio
  42. 8.7.5 Oblita Therapeutics BVBA Recent Developments
  43. 8.8 Merck & Co Inc
  44. 8.8.1 Merck & Co Inc Company Information
  45. 8.8.2 Merck & Co Inc Business Overview
  46. 8.8.3 Merck & Co Inc Chagas Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Merck & Co Inc Chagas Disease Drug Product Portfolio
  48. 8.8.5 Merck & Co Inc Recent Developments
  49. 8.9 Kancera AB
  50. 8.9.1 Kancera AB Company Information
  51. 8.9.2 Kancera AB Business Overview
  52. 8.9.3 Kancera AB Chagas Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Kancera AB Chagas Disease Drug Product Portfolio
  54. 8.9.5 Kancera AB Recent Developments
  55. 8.10 Humanigen Inc
  56. 8.10.1 Humanigen Inc Company Information
  57. 8.10.2 Humanigen Inc Business Overview
  58. 8.10.3 Humanigen Inc Chagas Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Humanigen Inc Chagas Disease Drug Product Portfolio
  60. 8.10.5 Humanigen Inc Recent Developments
  61. 8.11 Grupo Praxis Pharmaceutical SA
  62. 8.11.1 Grupo Praxis Pharmaceutical SA Company Information
  63. 8.11.2 Grupo Praxis Pharmaceutical SA Business Overview
  64. 8.11.3 Grupo Praxis Pharmaceutical SA Chagas Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Grupo Praxis Pharmaceutical SA Chagas Disease Drug Product Portfolio
  66. 8.11.5 Grupo Praxis Pharmaceutical SA Recent Developments
  67. 8.12 Daiichi Sankyo Co Ltd
  68. 8.12.1 Daiichi Sankyo Co Ltd Company Information
  69. 8.12.2 Daiichi Sankyo Co Ltd Business Overview
  70. 8.12.3 Daiichi Sankyo Co Ltd Chagas Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Daiichi Sankyo Co Ltd Chagas Disease Drug Product Portfolio
  72. 8.12.5 Daiichi Sankyo Co Ltd Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Chagas Disease Drug Value Chain Analysis
  2. 9.1.1 Chagas Disease Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Chagas Disease Drug Production Mode & Process
  6. 9.2 Chagas Disease Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Chagas Disease Drug Distributors
  9. 9.2.3 Chagas Disease Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst